Paradigm change in the treatment of gastrointestinal stromal tumors;Paradigmenwechsel in der therapie gastrointestinaler stromatumoren

Onkologe

Volumn 8, Issue 4, 2002, Pages 378-383

  Reichardt, P ^a,b   Pink, D ^a   Hohenberger, P ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Section of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERFERON; THALIDOMIDE;

CANCER SURGERY; CLINICAL TRIAL; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; LAPAROSCOPIC SURGERY; METASTASIS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SYMPTOM; TUMOR LOCALIZATION;

EID: 0346626792     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-002-0294-z     Document Type: Review

References (13)

1. Blanke CD, von Mehren M, Joensuu H, Roberts PJ, Eisenberg B, Heinrich M, Druker B, Tuveson D, Dimitrijevic S, Silberman SL, Demetri GD (2001) Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing C-KIT (CD117). Proc Am Soc Clin Oncol 20:1 a (Abstract)
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58
3. Druker B, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Katarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
4. Druker B, Sawyers CL, Katarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
5. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC (2001) The histological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 54:96-102
6. Joensuu H, Roberts PJ, Sarloma-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056
7. Krystal GW, Honsawek S, Litz J, Buchdunger E (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326
8. Miettinen M, Sarloma-Rikala M, Lasota J (1999) Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30:1213-1220
9. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12
10. Nishida T, Hirota S (2000) Biological and clinical review of stromal tumors of the gastrointestinal tract. Histol Histopathol 15:1293-1301
11. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136:383-389
12. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121
13. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423